Patricia Rosillo
Internal Medicine · Jbsa Ft Sam Houston, TXNPI 1730326679
Payments from drug & device makers
Across 55 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$243
- Livanova USA, Inc.$184
- Boehringer Ingelheim$117
- AbbVie$85
- UCB, Inc.$81
- GSK$75
- plus $416 from 16 others
What the payments were for
- Food & beverage$1,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $243 |
| Livanova USA, Inc. | 9 | $184 |
| Boehringer Ingelheim | 1 | $117 |
| AbbVie | 5 | $85 |
| UCB, Inc. | 3 | $81 |
| GSK | 4 | $75 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Genentech USA, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| Amgen | 2 | $32 |
| Neurelis, Inc. | 1 | $32 |
| AstraZeneca | 2 | $28 |
| Pfizer | 1 | $27 |
| Argenx US, Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Biogen | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Medtronic | 1 | $17 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$117
How this compares
$1,201 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 12 | $102,033 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $9,466 |
| Celecoxib | 57 | $3,721 |
| Duloxetine Hcl | 18 | $895 |
| Gabapentin | 37 | $694 |
| Nifedipine ErNifedipine | 13 | $585 |
| Omeprazole | 23 | $580 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $514 |
| Hydroxychloroquine Sulfate | 13 | $498 |
| Atorvastatin Calcium | 41 | $476 |
| Losartan Potassium | 24 | $375 |
| Cyclobenzaprine Hcl | 25 | $352 |
| Meloxicam | 42 | $329 |
| MethotrexateMethotrexate Sodium | 17 | $267 |
| Rosuvastatin Calcium | 17 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr | $19 | $9,46612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Jbsa Ft Sam Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.